| MeSH term | MeSH ID | Detail |
|---|---|---|
| Insulin Resistance | D007333 | 99 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Takahashi K et al. | Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. | 2014 | Transplant. Proc. | pmid:24655975 |
| Candinas D et al. | Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. | 1994 | Transplant. Proc. | pmid:7527959 |
| Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. | 1994 | Transplant. Proc. | pmid:7527960 | |
| Alessiani M et al. | Adverse effects of FK 506 overdosage after liver transplantation. | 1993 | Transplant. Proc. | pmid:7679825 |
| Nishikawa K et al. | Experimental studies of vascularized joint allografts in rats. | 1994 | Transplant. Proc. | pmid:7513482 |
| Klintmalm GB et al. | Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. | 1993 | Transplant. Proc. | pmid:7679826 |
| Fukuzawa M and Okada A | Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. | 1994 | Transplant. Proc. | pmid:7513483 |
| Kobayashi M et al. | FK 506 assay past and present--characteristics of FK 506 ELISA. | 1991 | Transplant. Proc. | pmid:1721258 |
| Warty VS et al. | Practical aspects of FK 506 analysis (Pittsburgh experience). | 1991 | Transplant. Proc. | pmid:1721259 |
| Bechstein WO et al. | Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. | 1996 | Transplant. Proc. | pmid:8623211 |
| Sher LS et al. | Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. | 1996 | Transplant. Proc. | pmid:8623212 |
| Mieles L et al. | Oral glucose tolerance test in liver recipients treated with FK 506. | 1990 | Transplant. Proc. | pmid:1689894 |
| Jang HJ et al. | Tacrolimus for rescue therapy in refractory renal allograft rejection. | 2000 | Transplant. Proc. | pmid:11119925 |
| Morita H et al. | Acceptance of skin xenografts (from guinea pig to mice) by portal venous and intravenous injections of donor hematolymphoid cells. | 2000 | Transplant. Proc. | pmid:10715422 |
| Taibi A et al. | Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. | 1998 | Transplant. Proc. | pmid:9636571 |
| Rodrigo E et al. | High initial blood levels of tacrolimus in overweight renal transplant recipients. | 2005 | Transplant. Proc. | pmid:15866635 |
| MartÃnez-Castelao A et al. | Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. | 2005 | Transplant. Proc. | pmid:16386539 |
| Spagnoletti G et al. | Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. | 2009 | Transplant. Proc. | pmid:19460509 |
| Armenta Bautista A et al. | Renal Transplantation in Second-Level Private Hospitals in the State of Mexico. | 2018 | Transplant. Proc. | pmid:29579825 |
| McCauley J et al. | Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. | 1991 | Transplant. Proc. | pmid:1721290 |
| Ciancio G et al. | Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. | 1996 | Transplant. Proc. | pmid:8623473 |
| Stratta RJ | Late acute rejection episodes after vascularized pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9636633 |
| Goulet O et al. | Small bowel transplantation alone or with the liver in children: changes by using FK506. | 1998 | Transplant. Proc. | pmid:9636636 |
| Hampel G et al. | Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors. | 1999 | Transplant. Proc. | pmid:10578279 |
| Ishibashi M et al. | Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period. | 1999 | Transplant. Proc. | pmid:10578281 |
| Yang S et al. | Characteristics of long-term immunosuppressive therapy in Chinese pediatric renal transplant patients: a single-center experience. | 2009 | Transplant. Proc. | pmid:20005361 |
| Seymen P et al. | Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters. | 2009 | Transplant. Proc. | pmid:20005364 |
| Schuller S et al. | Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. | 2005 | Transplant. Proc. | pmid:15848653 |
| Karabulut AB and Ara C | Melatonin ameliorates tacrolimus (FK-506)'s induced immunosupressive effect in rat liver. | 2009 | Transplant. Proc. | pmid:19545748 |
| Demirbas A et al. | FK 506 in simultaneous pancreas/kidney transplantation: the University of Miami experience. | 1997 | Transplant. Proc. | pmid:9365608 |
| Kurnatowska I et al. | Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. | 2011 | Transplant. Proc. | pmid:21996199 |
| Kliem V et al. | Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. | 1997 | Transplant. Proc. | pmid:9365627 |
| Murase N et al. | Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. | 1994 | Transplant. Proc. | pmid:7518139 |
| Fujisaki S et al. | Effects of preformed antibodies induced by whole blood transfusion on small bowel transplantation. | 1994 | Transplant. Proc. | pmid:7518140 |
| Gaweco AS et al. | Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. | 1995 | Transplant. Proc. | pmid:7533370 |
| Tze WJ et al. | FK 506--an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats. | 1992 | Transplant. Proc. | pmid:1376509 |
| Rao PN et al. | Prediction of early graft function by effluent levels of hyaluronic acid in clinical liver transplantation. | 1993 | Transplant. Proc. | pmid:7682366 |
| Armstrong VW et al. | Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. | 1995 | Transplant. Proc. | pmid:7533371 |
| Jordan ML et al. | Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. | 1991 | Transplant. Proc. | pmid:1721323 |
| Waller JR et al. | Effect of rapamycin in combination with calcineurin inhibitors, FK506 and cyclosporin, following arterial injury. | 2002 | Transplant. Proc. | pmid:12176449 |
| Weimer R et al. | sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. | 2005 | Transplant. Proc. | pmid:15919463 |
| Heilman RL et al. | Steroid avoidance immunosuppression in low-risk kidney transplant recipients. | 2005 | Transplant. Proc. | pmid:15919466 |
| Allers C et al. | Tacrolimus, daclizumab, sirolimus, and budesonide after small bowel transplantation in order to reduce nephrotoxicity. | 2002 | Transplant. Proc. | pmid:12034251 |
| Aktürk S et al. | Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection. | 2017 | Transplant. Proc. | pmid:28340806 |
| Funayama Y et al. | Changes in cell adhesion molecules after small bowel transplantation in rats. | 1995 | Transplant. Proc. | pmid:7533426 |
| Paul AA et al. | CMV retinitis and the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721354 |
| Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
| Hamano I et al. | Condyloma Acuminata of the Urethra in a Male Renal Transplant Recipient: A Case Report. | 2018 | Transplant. Proc. | pmid:30316397 |
| Wu MS et al. | Cyclosporine, but not FK 506 and rapamycin, enhances cell proliferation in mouse medullary thick ascending cultured cells. | 1998 | Transplant. Proc. | pmid:9838561 |
| Meiser BM et al. | The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083018 |
| Crespo-Leiro MG | Tacrolimus in heart transplantation. | 2003 | Transplant. Proc. | pmid:12962869 |
| Platz KP et al. | Impact of immunosuppression and acute rejection on hepatitis B recurrence. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123107 |
| Campos HH and Abbud Filho M | One-year follow-up of a Brazilian randomized multicenter study comparing tacrolimus versus cyclosporine in kidney transplantation. | 2002 | Transplant. Proc. | pmid:12176523 |
| Reyes J et al. | Intestinal transplantation in children: five-year experience. | 1996 | Transplant. Proc. | pmid:8908042 |
| Okano K et al. | Ameliorative effect of FK 506 on cold ischemia reperfusion injury of the rat liver. | 1994 | Transplant. Proc. | pmid:7520635 |
| Yoshimura N et al. | A new immunosuppressive agent, FK506, inhibits the expression of alloantigen-activated suppressor cells as well as the induction of alloreactivity. | 1989 | Transplant. Proc. | pmid:2468202 |
| McCauley J et al. | Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721387 |
| San Miguel C et al. | Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. | 2015 | Transplant. Proc. | pmid:26518930 |
| Miura K et al. | Development of the Intestinal Transplantation Model With Major Histocompatibility Complex Inbred CLAWN Miniature Swine. | 2016 | Transplant. Proc. | pmid:27320612 |
| Lee HK et al. | Expression of Endoplasmic Reticulum-Mediated Stress Proteins in FK506-Treated T-Lymphocytes. | 2016 | Transplant. Proc. | pmid:27320607 |
| Park JW et al. | Invasive pulmonary aspergillosis after living donor liver transplantation should be eradicated or not? A case report. | 2011 Jul-Aug | Transplant. Proc. | pmid:21839284 |
| Steinmueller T et al. | The effect of cyclosporine vs FK 506 on glucose metabolism. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083504 |
| Shapiro R et al. | A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083507 |
| Bhaloo S and Prasad GV | Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. | 2003 | Transplant. Proc. | pmid:14611983 |
| Iacona I et al. | Mycophenolic acid in combination with FK 506: a pharmacokinetic study in piglets after small-bowel transplantation. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123489 |
| Batten P et al. | Effect of cyclosporine A and FK 506 on human T cell responses to xenogeneic and allogeneic endothelium: relative resistance of T cell/porcine endothelial interactions. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123582 |
| Migita K and Eguchi K | FK 506-mediated T-cell apoptosis induction. | 2001 | Transplant. Proc. | pmid:11377532 |
| Omoto K et al. | Adverse events in renal transplantation under tacrolimus/mycophnolate mofetil immunosuppression: a single-center experience. | 2002 | Transplant. Proc. | pmid:12176591 |
| Nakache R et al. | Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization. | 2001 | Transplant. Proc. | pmid:11377533 |
| Baran DA et al. | A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results. | 2002 | Transplant. Proc. | pmid:12176595 |
| Canivet C et al. | T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus. | 2008 | Transplant. Proc. | pmid:19100403 |
| Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
| Tojimbara T et al. | Cyclosporine and tacrolimus both suppress activation of Kupffer cells in vitro. | 1996 | Transplant. Proc. | pmid:8658704 |
| Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
| Yuzawa K et al. | Topical immunosuppression in skin grafting with FK 506 ointment. | 1996 | Transplant. Proc. | pmid:8658707 |
| Aguirrezabalaga J et al. | Lipid profiles in liver transplantation in patients receiving tacrolimus or cyclosporin. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267192 |
| Varghese Z et al. | Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. | 1998 | Transplant. Proc. | pmid:9723384 |
| Ju MK et al. | Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety. | 2013 | Transplant. Proc. | pmid:23726602 |
| Reichenspurner H et al. | First experience with FK 506 for treatment of chronic pulmonary rejection. | 1995 | Transplant. Proc. | pmid:7540775 |
| Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
| Ueda D et al. | Influence of FK 506 on renal blood flow. | 1993 | Transplant. Proc. | pmid:7689280 |
| Ito T et al. | Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report. | Transplant. Proc. | pmid:26915883 | |
| Kim YE and Eun SC | Effect of FK506 ointment (Protopic) on rat skin allograft model. | 2014 | Transplant. Proc. | pmid:24815165 |
| Fung JJ et al. | Current status of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1712133 |
| Banerjee R et al. | Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267435 |
| Shingaki S et al. | Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. | Transplant. Proc. | pmid:29407317 | |
| Mehra MR et al. | A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267438 |
| Fujimura T et al. | Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506. | 1998 | Transplant. Proc. | pmid:9636413 |
| Yoshimura N et al. | Development of a macromolecular prodrug of FK 506: III: In vivo disposition of FK 506-dextran conjugate. | 1998 | Transplant. Proc. | pmid:9636415 |
| Umbro I et al. | Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients. | 2012 | Transplant. Proc. | pmid:22974867 |
| Tariciotti L et al. | Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. | 2016 | Transplant. Proc. | pmid:27932158 |
| Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
| Ott R et al. | Conversion from tacrolimus to Neoral in liver and kidney transplant recipients. | 2001 Nov-Dec | Transplant. Proc. | pmid:11750359 |
| Badiou S et al. | Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? | 2006 | Transplant. Proc. | pmid:16980076 |
| Pillet A et al. | Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia. | 2006 | Transplant. Proc. | pmid:16980083 |
| White SA et al. | Influence of delayed graft function in renal transplants from cadaveric or non-heart-beating donors. | 2000 | Transplant. Proc. | pmid:10701018 |
| Sens YA et al. | Posttransplant diabetes mellitus in renal transplant patients with hepatitis C virus. | 2004 | Transplant. Proc. | pmid:15194304 |
| Kliem V et al. | Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. | 1998 | Transplant. Proc. | pmid:9636509 |
| Williams ST et al. | Preliminary analysis of a randomized trial comparing microemulsion cyclosporine and tacrolimus for recipients of renal transplants from non-heart-beating donors. | 2000 | Transplant. Proc. | pmid:10701022 |
| Anglicheau D et al. | Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. | 2007 | Transplant. Proc. | pmid:17889118 |